COMPANY PROFILE

Century Therapeutics

Developing novel allogeneic iPSC-derived natural killer (NK) and T cell products with the potential to overcome many limitations of earlier generation cell therapies

Philadelphia, United StatesFounded 2018Biotech & Life Sciences

Valuation $278M Market cap · 2026

Revenue $109M Latest reported FY

EBITDA $9.4M Latest reported FY

Total funding $500M–1B Disclosed equity funding

About Century Therapeutics

Century Therapeutics, Inc. is a pioneering biotechnology company focused on developing transformative allogeneic cell therapies. These therapies are designed to treat both hematological (blood-related) and solid tumor malignancies, addressing significant unmet medical needs in the healthcare sector. The company leverages a comprehensive allogeneic cell therapy platform that includes industry-leading induced pluripotent stem cells (iPSCs), advanced differentiation techniques to generate immune effector cells from iPSCs, and CRISPR-mediated precision gene editing. Century Therapeutics operates primarily in the biotechnology and healthcare markets, serving patients with severe cancer conditions. The business model revolves around research and development (R&D) of innovative therapies, which are then brought to market through clinical trials and regulatory approvals. Revenue is generated through partnerships, licensing agreements, and eventual commercialization of successful therapies. Keywords: allogeneic cell therapies, hematological malignancies, solid tumors, iPSCs, CRISPR, biotechnology, immune effector cells, cancer treatment, R&D, healthcare.

Source: Dealroom company data

At a glance

Status: Operational
Founded: 2018
Headquarters: Philadelphia, United States
Listing: IPO 2021
Employees: 121
Open positions: 6
Dealroom signal: 29.1/100
Industry: Health
Sub-industry: BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Oncology, Rumoured $1B, Biotech and Pharma, Hard Tech, DT and LS, science-based
Business model: Manufacturing
Client focus: b2b
Investment activity: 1 company, latest Apr 2024
Capital deployed: —
Preferred round: ACQUISITION
Links: Website LinkedIn X

Latest news

Press, funding announcements and product moves mentioning Century Therapeutics.

See all news

Funding history

6 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
PRIVATE PLACEMENT VCOther financing	Jan 2026	$135M	—	Venrock · JDRF T1D Fund · RTW Investments · TCGX	↗
PRIVATE PLACEMENT VCOther financing	Apr 2024	$60M	—	Adage Capital · Casdin Capital · Octagon Capital Partners · Superstring Capital	↗

Showing the latest 2 of 6 recorded eventsBook a demo for the full funding history →

Financials

Revenue, earnings and profit over time

Revenue, earnings and other financial measures where available. Years marked “E” are estimates.

Year	Revenue	Growth	EBITDA	Margin
2026	$109M	0%	$9.4M	8.6%
2025	$109M	+1556.8%	$9.4M	8.6%
2024	$6.6M	+194.8%	−$107M	-1626.1%
2023	$2.2M	-57%	−$100M	-4467.2%
2022	$5.2M	—	−$121M	-2333.1%
2021	$0	—	−$95M	—
2020	$0	—	−$47M	—

Company filings, research estimates and Dealroom dataBook a demo for the full financial model →

Growth signals

Century Therapeutics website traffic

Latest recorded traffic for Century Therapeutics is 5.8K monthly website visits, up 11.5% over the last three months. Century Therapeutics's team grew 15.2% over the past year.

Latest monthly visits5.8K 3-month web change+11.5% 1-year team growth+15.2%

Monthly website visitsDec 2018–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Open positions

Openings linked to this company in Dealroom

Director, Large Scale Process DevelopmentBranchburg, New Jersey, United States, Northern America, Americas · Business Development · Aug 31, 2026 Director, Large Scale Process DevelopmentBranchburg, NJ · Business Development · Aug 27, 2026 Director, Translational SciencesWatertown, MA · Other · Jul 10, 2026 Associate Scientist/Sr. Associate Scientist/Scientist, Islet Process SciencesWatertown, MA · Other · Jul 6, 2026 Senior Research Associate/ Associate Scientist, Cell EngineeringPhiladelphia, PA · Other · Feb 24, 2026 Senior Research Associate, Analytical Science & TechnologyBranchburg, NJ · Data Science & Engineering · Feb 24, 2026

6 distinct openings shownExplore hiring signals →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
SISideROSFocused on accelerated development of innovative small molecules targeting tumour cells metabolism in high-risk cancers	Paris, France	Closed	—	$1.1M	$4.4M
ANAntegenesGenetic tests for personalized cancer risk prevention	Tartu, Estonia	Operational
BPBrenus PharmaProducing the widest panel of tumor associated antigens and resistance markers with a chemical labeling enable to induce cell death by patients' immune system	Clermont-Ferrand, France	Operational
UDUniversal Medical Imaging DiagnosticOffers a holistic alternative and complementary approach to overall health that uses non-invasive, non-radioactive and painless imaging of the whole body	Los Angeles, United States	Operational
PRProGeLifeDevelopment of drugs for the treatment of rare genetic aging diseases	Marseille, France	Operational
ABAC BioscienceA clinical stage biotech company focused on novel approaches to provide more effective treatments for solid tumor cancer patients	Ecublens, Switzerland	Operational
AUAutolusProgrammed T-cell immunotherapies for cancer and autoimmune diseases	London, United Kingdom	Operational
ITIGEM TherapeuticsImmuno-oncology IgE antibodies for treating solid tumors	London, United Kingdom	Operational